P090024/S013: Atellica IM Hepatitis B e Antigen (HBeAg)
FDA’s recorded scope: Approval for the Atellica CI Analyzer with Atellica Sample Handler configuration for Atellica IM HBcT2, aHBs2, HBeAg, aHBcM, aHBe2, HBsII & HBsII Conf assays.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name Siemens Healthcare Diagnostics. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 16, 2025 to Oct 17, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LOM appears in 2 of the 3 linked filings. The collection spans 2 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P030040, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 511 Benedict Ave., Tarrytown, NY, 10591. Recorded on P090024/S013, decision dated Oct 17, 2025.
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen); Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions.
FDA’s recorded scope: Approval for the Atellica CI Analyzer with Atellica Sample Handler configuration for Atellica IM HBcT2, aHBs2, HBeAg, aHBcM, aHBe2, HBsII & HBsII Conf assays.
FDA’s recorded scope: Approval for the Atellica CI Analyzer with Atellica Sample Handler configuration for Atellica IM HBcT2, aHBs2, HBeAg, aHBcM, aHBe2, HBsII & HBsII Conf assays.
FDA’s recorded scope: Approval for the implementation of a particle size analyzer utilized for the in-process testing of paramagnetic particles.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Atellica IM Hepatitis B e Antigen (HBeAg)P090024/S013 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
Atellica IM Hepatitis B core IgM (aHBcM)P030040/S024 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
| Siemens Healthcare Diagnostics | PMA supplement | Jul 16, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.